Clinical Data

Co-primary endpoints met with response rates of 74.5% for dysmenorrhea (menstrual pain) and 58.5% for non-menstrual pelvic pain (p-values < 0.0001)

Women receiving relugolix combination therapy, on average, had a 73.3% reduction on the Numerical Rating Scale for dysmenorrhea from 7.3 (severe pain) to 1.8 (mild pain)

Achieved all seven key secondary endpoints, including dyspareunia (painful intercourse) and a greater proportion of women not using opioids, with a generally well-tolerated safety profile including minimal bone mineral density loss